Next year will be a “landmark” one for GlaxoSmithKline, according to CEO Emma Walmsley — though many of the biggest changes she forecasted may not become evident until next year.
On next year’s agenda: fresh data from clinical trials of a vaccine for respiratory syncytial virus, a very common childhood illness; a Food and Drug Administration decision for daprodustat, GSK’s experimental treatment for a type of anemia; and the de-merger of GSK’s consumer business from its pharmaceutical arm — twenty-one years after the massive merger that created GlaxoSmithKline in the first place.
About the Author Reprints
